Evidence map›Paper›PMID 35135489›Full record

ArticleBMC cancer2022

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.

Toshihiko Kaneda, Takayasu Kurata, Tomoko Yoshida, Kayoko Kibata, Hiroshige Yoshioka, Hiroaki Yanagimoto, Kazuhiko Takeda, Takao Yoshida, Koji Tsuta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toshihiko KanedaDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata City, Osaka, 573-1191, Japan. kaneda.toshihiko.0412@gmail.com.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata City, Osaka, 573-1191, Japan.
Tomoko YoshidaDiscovery Technology Research, Ono Pharmaceutical, Co., Ltd., Osaka, Japan.
Kayoko KibataDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata City, Osaka, 573-1191, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata City, Osaka, 573-1191, Japan.
Hiroaki YanagimotoDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazuhiko TakedaResearch Center of Oncology, Ono Pharmaceutical, Co., Ltd., Osaka, Japan.
Takao YoshidaResearch Center of Oncology, Ono Pharmaceutical, Co., Ltd., Osaka, Japan.
Koji TsutaCorporate Sponsored Research Programs for Cancer Immunogenomics, Kansai Medical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy and immunohistochemical analysis, this technique is not yet considered foolproof for predicting a favorable outcome of PD-1 antibody therapy. We aimed to predict the efficacy of nivolumab based on a comprehensive analysis of RNA expression at the gene level in advanced NSCLC.

methodsThis was a retrospective study on patients with NSCLC who were administered nivolumab at the Kansai Medical University Hospital. To identify genes associated with response to anti-PD-1 antibodies, we grouped patients into responders (complete and partial response) and non-responders (stable and progressive disease) to nivolumab therapy. Significant genes were then identified for these groups using Welch's t-test.

resultsAmong 42 analyzed cases (20 adenocarcinomas and 22 squamous cell carcinomas), enhanced expression of MAGE-A4, BBC3, and OTOA genes was observed in responders with adenocarcinoma, and enhanced expression of DAB2, HLA-DPB,1 and CDH2 genes was observed in responders with squamous cell carcinoma.

conclusionsThis study predicted the efficacy of nivolumab based on a comprehensive analysis of mRNA expression at the gene level in advanced NSCLC. We also revealed different gene expression patterns as predictors of the effectiveness of anti PD-1 antibody therapy in adenocarcinoma and squamous cell carcinoma.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaAdultAgedAged, 80 and overAntigens, CDAntigens, NeoplasmApoptosis Regulatory ProteinsBiomarkers, TumorCadherinsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDrug Resistance, NeoplasmFemaleGene ExpressionGPI-Linked ProteinsAdaptor Proteins, Signal TransducingAntigens, CDAntigens, NeoplasmApoptosis Regulatory ProteinsBBC3 protein, humanBiomarkers, TumorCadherinsCDH2 protein, humanDAB2 protein, humanGPI-Linked ProteinsHLA-DPB1 antigenHLA-DP beta-ChainsImmune Checkpoint InhibitorsMAGEA4 protein, humanNeoplasm ProteinsNivolumabOTOA protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene ProteinsRNA, MessengerAdvanced non-small cell lung cancerAnti PD-1 antibodyNivolumabTranscriptome

Identifiers

PMID35135489
PMCPMC8822674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.